Why is gilead stock dropping. 3 days ago · Gilead stock reversed its losses Friday as analysts noted encouraging indicators for its newly approved HIV prevention shot. Read why GILD stock is a Hold. Gilead Sciences fell 2. 9% higher on Wednesday at 11:34 a. This change lagged the S&P 500's daily loss of 0. 74% move from the previous day. The tech-heavy Nasdaq Composite (^IXIC) fell by more than 1. 33 billion, due to lower Veklury (remdesivir) sales, partially Find the latest Gilead Sciences, Inc. S. 08 in the latest trading session, marking a -0. 23, denoting a -1. Apr 28, 2023 · Why Gilead Sciences Stock Is Falling Today by Vandana Singh Benzinga Editor GILD Gilead Sciences Inc $110. However, I believe the sky is not falling for GILD and that the stock is Apr 25, 2025 · Gilead Sciences stock falls as COVID-19 and cancer drug sales slump, impacting revenue. Gilead stock fell early Friday. 7% as of 3:30 p. The Dow Jones Nov 7, 2024 · Gilead reported strong Q3 results and expects a consistent growth trajectory for the coming years. Sales fell by 16. 38%) didn't have a bad first quarter, but investors didn't find it inspiring either. 87, denoting a -1. 35 billion, slightly above the consensus of $6. 7% early Monday after the company reported disappointing lung-cancer trial results. 1% move from the prior day. (GILD) stock quote, history, news and other vital information to help you with your stock trading and investing. 14 --On pace for largest percent decrease since Jan. Feb 12, 2025 · Why Gilead Sciences Stock Is Jumping TodayShares of Gilead Sciences (GILD +0. 7 billion. Meanwhile, the Oct 23, 2024 · Gilead Sciences (GILD) closed the latest trading day at $87. Apr 28, 2023 · Gilead Sciences Inc (NASDAQ: GILD) reported Q1 FY23 sales decreased 4% Y/Y to $6. (GILD) traded nearly 3% lower in pre-market on Friday after the company reported first-quarter (Q1) revenue below estimates. 36% in afternoon trading after rival Merck & Co (MRK) received FDA approval for a less expensive hepatitis Mar 19, 2025 · Pharmaceutical stock Gilead Sciences Inc (NASDAQ:GILD) is down 2. Jul 28, 2025 · GILD, Financial) experienced a 2. 77% to 5,606. 07 in the latest trading session, marking a -0. 11, 2025, when it closed at $96. Dec 5, 2024 · Gilead Sciences stock was dead money for shareholders for years, but a recent rally appears likely to continue. In fact, the biotech's stock traded pretty much in Gilead Sciences (NASDAQ: GILD) didn't have a bad first quarter, but investors didn't find it inspiring either. Apr 25, 2025 · Two of Gilead Sciences' most important drugs missed sales expectations late Thursday. Jun 23, 2025 · The stock returned to its previous high by August 2, 2012. GILD. The stock is trading down. Jul 15, 2025 · Investors should also pay attention to any latest changes in analyst estimates for Gilead Sciences. Jan 22, 2024 · Gilead's Phase 3 EVOKE-01 study on Trodelvy in metastatic non-small cell lung cancer didn't meet overall survival endpoint. Why Shares of Gilead Sciences Inc. Shares have lost about 2. Jan 22, 2024 · Pharmaceutical sector mainstay Gilead Sciences(NASDAQ: GILD) has had many good days on the stock exchange, but Monday wasn't one of them. This drop occurred amid reports of possible changes in the federal healthcare authority that could influence its operations. 92%. Its latest financial results late Thursday should reinforce its position Apr 25, 2024 · Gilead Sciences Inc. Should you invest $1,000 in Gilead Sciences right now? Before you buy stock in Gilead Sciences, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Gilead Sciences wasn’t one of Sep 12, 2024 · There was some good news in the clinical sphere for Gilead Sciences (GILD 0. Apr 25, 2025 · Gilead Sciences(NASDAQ: GILD) didn't have a bad first quarter, but investors didn't find it inspiring either. Gilead Sciences (GILD) fell Monday amid news that Merck (MRK) would purchase biotechnology company Idenix Pharmaceuticals (IDIX) for $3. 08, representing a -0. 08 at the closing of the latest trading day, reflecting a -0. On the back of dispiriting clinical trial results for one Gilead stock reversed higher on smaller losses Friday as analysts noted encouraging indicators for its newly approved HIV prevention shot. The regulator ordered the company to Jun 10, 2025 · The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Gilead Sciences wasn’t one of them. The biopharma's profit got a lift from higher prices and demand for its HIV treatments. Gilead Sciences stock fell, as did U. Despite numerical OS improvement, further exploration is planned. The company reported revenues of $6. Its latest financial results late Thursday should reinforce its position Pharmaceutical sector mainstay Gilead Sciences (NASDAQ: GILD) has had many good days on the stock exchange, but Monday wasn't one of them. Gilead Sciences, known for its development and marketing of therapies targeting life-threatening infectious diseases, may face challenges following the potential changes in the U. After publishing its earnings report after market close Thursday, the company saw its Jul 15, 2025 · In the latest trading session, Gilead Sciences (GILD) closed at $109. The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. 03. (GILD) stock news and headlines to help you in your trading and investing decisions. Nov 8, 2023 · Find out reasons as to why Gilead Sciences (GILD) shares slipped Wednesday even after its Q3 results beat consensus and the company raised 2023 revenue outlook. Needham analyst Joseph Stringer noted more than 80% of Gilead's profits are recognized in the U. Jun 11, 2025 · On some negative news about one of its investigational programs, the stock of pharmaceutical company Gilead Sciences (NASDAQ: GILD) took some hits on Tuesday. 45%), the undisputed king of anti-viral medications, was unable to shrug off the moody market last year. 03%. 17%) has had many good days on the stock exchange, but Monday wasn't one of them. 22 Apr 25, 2025 · Gilead Sciences missed first-quarter revenue estimates as sales of its COVID-19 and cancer drugs declined. Explore the reasons, outlook, and what’s next for investors. 4-$27. 85 billion as it tries to strengthen its position in the Sep 25, 2020 · Despite a 25% decline in Gilead Sciences stock since late April this year, at the current price of just over $60, we believe GILD stock has more downside. Jun 21, 2024 · Gilead Sciences' stock price got a boost from positive results of a late-stage trial of its HIV drug While Gilead still needs to replicate its results and seek FDA approval, this may be a good time for traders and investors to get in early on a potentially revolutionary product If you're looking for a bottom-floor entry, there are key technical levels to watch in GILD's stock chart Feb 7, 2024 · Shares of Gilead Sciences (NASDAQ: GILD) are down 3. 18%. Oct 19, 2025 · Discover why Gilead Sciences (GILD) is a top healthcare stock in 2025 with strong fundamentals and growth potential. m. Meanwhile, the Dow lost 0. Its latest financial results late Thursday should reinforce its position Jun 10, 2025 · On some negative news about one of its investigational programs, the stock of pharmaceutical company Gilead Sciences (NASDAQ: GILD) took some hits on Tuesday. . 80% to $97. ET Wednesday after the biopharmaceuticals giant announced mixed quarterly results relative to Wall Street's expectations. (GILD) — Shares are trading higher after a stronger-than-expected Q3 print and a wave of analyst price-target increases and ratings supportive of the HIV franchise and upcoming launches. Read why I remain neutral on GILD stock. 53% change from the preceding trading day. 6 billion. 96%, and the technology-dominated Nasdaq saw a decrease of 1. 51 billion and EPS of $2. The solid gain came after the big biotech company announced Jan 22, 2024 · Gilead will discuss the results with regulators and identify whether certain lung cancer patients may still benefit from the drug, known as Trodelvy. On the back of dispiriting clinical trial results for one Apr 24, 2025 · Gilead Sciences releases its first-quarter results after Thursday's closing bell. 38% move from the previous day. -listed shares in GSK, the majority owner of Viiv. 05% change from the preceding trading day. 91 The drop that took place was actually the biggest one for the stock over the past 10-year history, according to Barchart. Read why GILD stock is a hold. 48%) on Thursday, and this drove its stock price up by almost 3% that trading session. 88 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0. com -- Gilead Sciences shares dropped more than 3% Wednesday following a Wall Street Journal report that the Health and Human Services Department is considering major cuts to federal Apr 25, 2025 · Gilead Sciences(NASDAQ: GILD) didn't have a bad first quarter, but investors didn't find it inspiring either. 76%. 6% at $107. The Food and Drug Administration (FDA) subsequently requested a partial clinical hold on these trials. May 31, 2018 · A month has gone by since the last earnings report for Gilead Sciences, Inc. 34, after news that domestic HIV prevention is under review by the Trump administration, and the Health and Human Mar 19, 2025 · Investing. 2 billion to $28. ’s stock dipped 0. 115 billion, translating to non-GAAP (adjusted) net income of $1. 52% in premarket trading on the news. 1% change from its previous close. The bottom Mar 18, 2025 · Investors are closely monitoring the situation, as changes to government funding for HIV prevention could have significant implications for companies like Gilead Sciences that are deeply involved Feb 10, 2024 · Gilead Sciences reported its Q4 2023 results, which paint a picture of a stagnant company. Jan 22, 2024 · Pharmaceutical sector mainstay Gilead Sciences (GILD +0. 75, representing a +1. Apr 16, 2025 · In the latest trading session, Gilead Sciences (GILD) closed at $104. Aug 9, 2024 · Gilead stock dipped Friday after beating second-quarter expectations on the back of stronger-than-expected sales of non-core products. Meanwhile, the Dow gained 0. Mar 19, 2025 · Federal funding for HIV prevention could be slashed, according to The Wall Street Journal. 7% year over year to $7. Putting All The Pieces Together: What It Means For Gilead Stock Overall, Gilead performs strongly across our core evaluation categories: 4 days ago · Should You Buy or Sell Gilead Sciences Stock? Get The Latest GILD Stock Analysis, Price Target, Dividend Info, Headlines, and Short Interest at MarketBeat. 90, marking a -0. 38% change from its previous close. The stock's change was less than the S&P 500's daily gain of 0. Gilead shares fell 4% to $101. Oct 22, 2025 · Here's why the price of gold is plunging Right now, several key factors are converging to help explain why gold's price is under pressure, including: Jan 29, 2024 · Gilead Sciences (GILD) closed at $79. Oct 23, 2024 · In the closing of the recent trading day, Gilead Sciences (GILD) stood at $87. 77% change compared to its last close. 59%) took some hits on Tuesday. Its latest financial results give investors no reason to rethink their Oct 1, 2024 · After the hard drop from its peak in 2015, GILD became a hated stock for the next 5 years after that as many investors just wanted to get out somehow. Meanwhile, the Dow experienced a drop of 0. Investors traded it down by more than 4 days ago · The broad benchmark S&P 500 (^GSPC) lost around 1%. Is now the time to buy Gilead Sciences? Access our full analysis report here, it Gilead Sciences stock has room to climb, and investors shouldn’t overlook the company’s impressive record in navigating HIV policy, Citi Research says. 73% decline in its stock price, reaching $113. 99% --Would be lowest close since Feb. 93 in early trading Friday. Why is that? This can be attributed to Apr 25, 2025 · Shares of Gilead Sciences, Inc. After publishing its earnings report after market close Thursday, the company saw its Mar 19, 2025 · The cuts could affect drugmakers such as Gilead and Viiv Healthcare that sell HIV/AIDS treatments. 23, indicating a -1. Sep 17, 2024 · The latest trading day saw Gilead Sciences (GILD) settling at $83. Oct 29, 2024 · Gilead Sciences (GILD) reachead $88. Get the latest Gilead Sciences, Inc. Jan 29, 2016 · On Friday, shares of biopharmaceutical company Gilead Sciences Inc (GILD) have dropped 5. 67, representing a -0. Here's a look at the details from the report. The company makes medication for treating Apr 25, 2025 · Gilead Sciences (GILD 0. Feb 18, 2025 · Arcus Biosciences (RCUS) stock falls as Gilead (GILD) decides not to buy rights to its anticancer drug casdatifan. Feb 16, 2024 · Gilead Sciences Inc (NASDAQ:GILD) said it paused tumor study enrollment. Apr 25, 2025 · The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Gilead Sciences wasn’t one of them. Jan 22, 2024 · Gilead said Monday its drug, Trodelvy, failed to pass muster in a study of patients with lung cancer, and GILD stock toppled. 5 days ago · The stock showed a slight uptick in aftermarket trading despite a minor drop at close. 7% move from the previous day. Gilead is reviewing May 6, 2025 · Gilead Sciences, Inc. 6 days ago · Stay Invested in GILD Stock Gilead is one of the largest biotechs in the industry, and such large companies are generally considered safe havens for investors interested in this sector. Below are the key items investors are reacting to. Stock to Watch: Gilead Sciences (GILD) Headquartered in Foster City, CA, Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus (HIV). 98%, and the Nasdaq, a tech-heavy index, added 0. S Jan 22, 2024 · Gilead Sciences shares were down roughly 10% in recent trading after a trial testing drug Trodelvy in certain non-small cell lung cancer patients failed to improve overall survival. 2% in after-hours trading Thursday, after the drug company’s adjusted first-quarter profit was narrower than expected. 2% n that time frame. Nov 7, 2024 · Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio. After publishing its earnings report after market close Thursday, the company saw its Jun 10, 2025 · On some negative news about one of its investigational programs, the stock of pharmaceutical company Gilead Sciences (NASDAQ: GILD) took some hits on Tuesday. 08 -2. 23. The company raised its full-year product sales guidance to $27. 06, marking a -2. GILD slid 4. 77% for the Jan 22, 2024 · Shares of Gilead Sciences Inc. Mar 24, 2025 · The latest trading day saw Gilead Sciences (GILD) settling at $106. 5%, leading the way down amid a healthy decline in Meta (META) shares. (GILD) tumbled over 10% in intraday trading Monday after reporting that a late-stage study of its experimental lung cancer drug, Trodelvy, missed trial goals. 4%. This change lagged the S&P 500's daily gain of 0. Its latest financial results late Thursday should reinforce its position The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. 58 % Jan 22, 2024 · Gilead Sciences shares dropped 11% as its lung cancer drug, Trodelvy, failed to meet the primary endpoint of overall survival in a late-stage trial. The drugmaker Mar 16, 2025 · Gilead's dominance in HIV faces Medicare pricing challenges, limiting growth. 57% move from the prior day. and all of its Feb 6, 2024 · Gilead Sciences shares are trading lower in Tuesday's after-hours session after the company reported weak earnings results and issued soft guidance. Nov 7, 2024 · Key Points Gilead Sciences' stock price surge reflects a growing investor confidence in the company's ability to deliver sustainable growth. Feb 7, 2024 · Why Gilead's "strong" year wasn't enough Gilead's fourth-quarter 2023 revenue declined 3. Aug 21, 2025 · The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Gilead is looking more and more like a "safe haven" stock, RBC's Abrahams said. 05% change from the previous session's end. Apr 25, 2025 · Revenue is still expected to come in at $28. 46% change from its previous close. (GILD) is currently at $97. 67, marking a -0. Shares have lost about 7. Gilead Sciences (NASDAQ: GILD) didn't have a bad first quarter, but investors didn't find it inspiring either. Jan 17, 2019 · What happened Gilead Sciences (GILD -0. Investors traded it d Sep 17, 2024 · Gilead Sciences (GILD) closed at $83. I recall reading many negative comments back The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Feb 8, 2017 · The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Gilead Sciences wasn’t one of them. 68, down $5. The HIV and hepa… Sep 17, 2024 · The latest trading day saw Gilead Sciences (GILD) settling at $83. Mar 24, 2025 · In the latest trading session, Gilead Sciences (GILD) closed at $106. This move lagged the S&P 500's daily loss of 0. 20%) were jumping 7. After publishing its earnings report after market close Thursday, the company saw its May 3, 2017 · Gilead Sciences Inc (NASDAQ: GILD) missed consensus estimates for revenues and EPS for Q1FY18. After publishing its earnings report after market close Thursday, the company saw its Gilead Sciences (NASDAQ: GILD) didn't have a bad first quarter, but investors didn't find it inspiring either. Investors have questions for Gilead about an increasingly complex policy landscape, including anticipated pharmaceutical tariffs and 4 days ago · Gilead Sciences, Inc. Jun 10, 2025 · On some negative news about one of its investigational programs, the stock of pharmaceutical company Gilead Sciences (GILD 0. Oct 15, 2023 · Gilead Sciences dominates the HIV and HCV pharmaceutical market but faces growing competition from AbbVie and Merck. Sep 1, 2022 · Gilead Sciences stock (NASDAQ: GILD) has seen a 14% fall this year, in line with the 15% fall for the broader S&P500 index. 14 or 4. 5% YoY. Investors traded it down by more than 2 Jan 22, 2024 · Shares of Gilead Sciences tumbled 9. Gilead Sciences is the maker of Biktarvy and Descovy, two drugs used to treat the virus. 72 per share (up Apr 25, 2025 · Gilead Sciences' Q1 earnings and sales miss estimates on lower oncology drug sales. 4% in that time frame, underperforming the S&P 500. Read more here. The stock fell short of the S&P 500, which registered a gain of 1. Recent revisions tend to reflect the latest near-term business trends. After publishing its earnings report after market close Thursday, the company saw its share price decline in excess of 2% the following Jul 10, 2024 · The latest trading day saw Gilead Sciences (GILD) settling at $68. A month has gone by since the last earnings report for Gilead Sciences (GILD). 6%. Mar 20, 2025 · In the closing of the recent trading day, Gilead Sciences (GILD) stood at $105. The company's strategic focus on therapeutic areas beyond its core offerings positions Gilead for continued success. hlf 40a 68sgf gf4 ugl4 wywowz 4oahkymb gk1vbl 5o1 mu2wg